Klotho and Postmenopausal Hormone Replacement Therapy in Women with Chronic Kidney Disease
- Author:
Yoo Jin PARK
1
;
Jun Mo KIM
Author Information
- Publication Type:Review
- Keywords: Estrogen replacement therapy; Hormone replacement therapy; Postmenopause; Renal insufficiency, chronic
- MeSH: Aged; Aging; Estrogen Replacement Therapy; Estrogens; Female; Hormone Replacement Therapy; Humans; Kidney; Korea; Menopause; Mortality; Postmenopause; Prevalence; Renal Insufficiency, Chronic; Renin-Angiotensin System; Superoxides
- From:Journal of Menopausal Medicine 2018;24(2):75-80
- CountryRepublic of Korea
- Language:English
- Abstract: Kidney function is highly susceptible to age-related changes, with chronic kidney disease (CKD) serving as an important cause of morbidity and mortality in older patients. The prevalence of CKD in Korea is higher among the elderly, relative to the general population, with the most significant increases seen following the onset of menopause. Under normal conditions, estrogen attenuates renal superoxide production and protects the kidney from oxidative damage. As estrogen levels are known to decrease by as much as 80% during menopause, this represents a significant risk for older women. Postmenopausal hormone replacement therapy (HRT) modulates the renin-angiotensin system, thereby reducing the progressive deterioration of renal function. Use of estrogen-based HRT has been shown to ameliorate renal function in postmenopausal women, and delay CKD progression. Renal expression of klotho, an important suppressor of aging, is markedly decreased in CKD patients, making it a promising candidate for use as a prognostic biomarker in CKD. Here, we review the key links between renal function, sex, age, and estrogen levels during menopause, and discuss the use of postmenopausal HRT in CKD attenuation.
